Clinical Investigators and the Pharmaceutical Industry

Clinical Investigators and the Pharmaceutical Industry Thomas Bodenheimer; The New England Journal of Medicine

[1]  B. Woodward,et al.  Challenges to human subject protections in US medical research. , 1999, JAMA.

[2]  P. Gøtzsche,et al.  Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. , 1999, JAMA.

[3]  M. Friedberg,et al.  Evaluation of conflict of interest in economic analyses of new drugs used in oncology. , 1999, JAMA.

[4]  R. Temple,et al.  Are surrogate markers adequate to assess cardiovascular disease drugs? , 1999, JAMA.

[5]  T. Fleming,et al.  Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. , 1999, JAMA.

[6]  M. Larkin.  Whose article is it anyway? , 1999, The Lancet.

[7]  C. Stein,et al.  Making medicines safer--the need for an independent drug safety board. , 1998, The New England journal of medicine.

[8]  P. Rochon,et al.  The evolution of clinical trials: inclusion and representation. , 1998, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[9]  J. Hoey,et al.  Constraints of interest: lessons at the Hospital for Sick Children. , 1998, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[10]  K. Fleming,et al.  Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. , 1998, The New England journal of medicine.

[11]  Henry T. Stelfox,et al.  Conflict of interest in the debate over calcium-channel antagonists. , 1998, The New England journal of medicine.

[12]  K. Shine.  Some imperatives for clinical research. , 1997, JAMA.

[13]  Melissa S. Anderson,et al.  Withholding research results in academic life science. Evidence from a national survey of faculty. , 1997, JAMA.

[14]  C. Furberg,et al.  The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS) , 1997, JAMA.

[15]  M. Cho,et al.  The Quality of Drug Studies Published in Symposium Proceedings , 1996, Annals of Internal Medicine.

[16]  D. Rennie,et al.  Influences on the Quality of Published Drug Studies , 1996, International Journal of Technology Assessment in Health Care.

[17]  D. Rennie,et al.  Authorship! Authorship! Guests, ghosts, grafters, and the two-sided coin. , 1994, JAMA.

[18]  P. Rochon,et al.  A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. , 1994, Archives of internal medicine.

[19]  I Chalmers,et al.  Underreporting research is scientific misconduct. , 1990, JAMA.

[20]  R. Davidson.  Source of funding and outcome of clinical trials , 1986, Journal of general internal medicine.

[21]  C M Kunin.  Clinical investigators and the pharmaceutical industry. , 1978, Annals of internal medicine.